The decrease in prostate cancer screening rates was the smallest among 5 cancers studied.
Neoadjuvant chemotherapy prior to radical nephroureterectomy for upper tract urothelial carcinoma may improve pathologic outcomes regardless of age, new data suggest.
Investigators report increased risks for adverse pathology and 90-day readmission.
Greater consumption of healthful plant-based foods is associated with significantly reduced risks for advanced, lethal, and fatal prostate cancer, especially among men younger than 65 years.
The protective effect of high body mass index is not related to use of higher doses of chemotherapy, investigators reported.
A mitomycin-containing reverse thermal gel could provide an alternative to repetitive surgeries for low-grade intermediate-risk NMIBC, according to investigators.
The risk for alzheimer disease decreased with increased dosing of BCG.
In addition to similar rates of overall survival, patients undergoing partial and radical cystectomy had comparable rates of upstaging to pT3-4 disease.
In this small study, even patients with high-risk tumors appeared to benefit from nephron-sparing surgery.
The risks for metastasis, biochemical recurrence, and overall mortality are unaffected, according to investigators.
If validated, the EpiCheck® assay may identify more patients who can safely delay or avoid nephroureterectomy.
New study findings “are critically important in patient counseling and surgical planning, particularly for patients with risk factors for renal deterioration,” according to investigators.
A phase 2 exploratory study of men with low- and intermediate-risk localized prostate cancer demonstrated the oncologic benefit of enzalutamide treatment vs active surveillance.
Investigators concluded that there is minimal to no clinical value in surveillance for pulmonary recurrence after T1a RCC resection.
Older age independently predicted significant 48% lower odds of the gold standard treatment of NAC and radical cystectomy.
Study results support an attempt at bladder preservation in patients with BCG-unresponsive nonmuscle-invasive bladder cancer.
At prostate cancer diagnosis, clinical T stage was significantly higher among 5-ARI users compared with nonusers.
Five-year survival rates following nephrectomy for renal cell carcinoma are higher among patients with favorable vs unfavorable histology.
In a small study, most BCG-unresponsive patients who were initially managed conservatively ultimately underwent cystectomy.